Genetics of dementia

The Lancet

Volumn 383, Issue 9919, 2014, Pages 828-840

  Loy, Clement T ^a,b,c   Schofield, Peter R ^b,d   Turner, Anne M ^e   Kwok, John B J ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e SYDNEY CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; ENVIRONMENTAL FACTOR; FAMILY; FAMILY HISTORY; FRONTOTEMPORAL DEMENTIA; GENE; GENE MUTATION; GENETIC COUNSELING; GENETIC SCREENING; GENETIC VARIABILITY; HIGH RISK PATIENT; HUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

AGED; ALZHEIMER DISEASE; DEMENTIA; GENETIC COUNSELING; GENETIC LINKAGE; GENETIC TESTING; GENETIC VARIATION; HUMANS; MIDDLE AGED; MUTATION; PEDIGREE; PHENOTYPE;

EID: 84896707237     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)60630-3     Document Type: Review

References (144)

1. Slooter AJ, Cruts M, Kalmijn S, et al. Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study. Arch Neurol 1998; 55: 964-68.
2. Cruts M. Alzheimer disease and frontotemporal dementia mutation database. 2012. http://www.molgen.ua.ac.be/admutations/ (accessed April 26, 2012).
3. Gadjusek DC, Alpers M. Genetic studies in relation of kuru. I. Cultural, historical, and demographic background. Am J Hum Genet 1972; 24: S1-S38.
4. Teare DM, Barrett JH. Genetic linkage studies. Lancet 2005; 366: 1036-44.
5. HGMIS. Genetic disease information-pronto! http://www.ornl.gov/sci/ techresources/Human-Genome/medicine/assist.shtml (accessed April 26, 2012).
6. Attia J, Ioannidis JP, Thakkinstian A, et al. How to use an article about genetic association: A: background concepts. JAMA 2009; 301: 74-81.
7. Kraft P, Hunter DJ. Genetic risk prediction-are we there yet? N Engl J Med 2009; 360: 1701-03.
8. Wilson BJ, Qureshi N, Santaguida P, et al. Systematic review: family history in risk assessment for common diseases. Ann Intern Med 2009; 151: 878-85.
9. Rockwood K, Howard K, Thomas VS, et al. Retrospective diagnosis of dementia using an informant interview based on the brief cognitive rating scale. Int Psychogeriatr 1998; 10: 53-60.
10. Barber R, Snowden JS, Craufurd D. Frontotemporal dementia and Alzheimer's disease: retrospective differentiation using information from informants. J Neurol Neurosurg Psychiatry 1995; 59: 61-70.
11. Velakoulis D, Walterfang M, Mocellin R, Pantelis C, McLean C. Frontotemporal dementia presenting as schizophrenia-like psychosis in young people: clinicopathological series and review of cases. Br J Psychiatry 2009; 194: 298-305.
12. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012; 367: 795-804.
13. Rossor MN, Fox NC, Mummery CJ, Schott JM, Warren JD. The diagnosis of young-onset dementia. Lancet Neurol 2010; 9: 793-806.
14. University of Washington. Genetests. http://www.ncbi.nlm.nih.gov/sites/ GeneTests/?db=GeneTests (accessed April 26, 2012).
15. Menendez M. Pathological and clinical heterogeneity of presenilin 1 gene mutations. J Alzheimers Dis 2004; 6: 475-82.
16. Moscarillo TJ, Holt H, Perman M, et al. Knowledge of and attitudes about Alzheimer disease genetics: report of a pilot survey and two focus groups. Community Genet 2007; 10: 97-102.
17. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-44.
18. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 263-69.
19. Alzheimer's Disease International. World Alzheimer report. London: Alzheimer's Disease International, 2009.
20. Goldman JS, Hahn SE, Catania JW, et al. Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genet Med 2011; 13: 597-605.
21. Raux G, Guyant-Marechal L, Martin C, et al. Molecular diagnosis of autosomal dominant early onset Alzheimer's disease: an update. J Med Genet 2005; 42: 793-95.
22. Rovelet-Lecrux A, Hannequin D, Raux G, et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 2006; 38: 24-26.
23. Campion D, Dumanchin C, Hannequin D, et al. Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet 1999; 65: 664-70.
24. Janssen JC, Beck JA, Campbell TA, et al. Early onset familial Alzheimer's disease: mutation frequency in 31 families. Neurology 2003; 60: 235-39.
25. Zekanowski C, Styczynska M, Peplonska B, et al. Mutations in presenilin 1, presenilin 2 and amyloid precursor protein genes in patients with early-onset Alzheimer's disease in Poland. Exp Neurol 2003; 184: 991-96.
26. Lleo A, Blesa R, Queralt R, et al. Frequency of mutations in the presenilin and amyloid precursor protein genes in early-onset Alzheimer disease in Spain. Arch Neurol 2002; 59: 1759-63.
27. Kauwe JS, Jacquart S, Chakraverty S, et al. Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer's disease presenilin 1 mutation. Ann Neurol 2007; 61: 446-53.
28. Cruchaga C, Haller G, Chakraverty S, et al. Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer's disease families. PloS One 2012; 7: e31039.
29. Tanahashi H, Kawakatsu S, Kaneko M, Yamanaka H, Takahashi K, Tabira T. Sequence analysis of presenilin-1 gene mutation in Japanese Alzheimer's disease patients. Neurosci Lett 1996; 218: 139-41.
30. Ryan NS, Rossor MN. Correlating familial Alzheimer's disease gene mutations with clinical phenotype. Biomark Med 2010; 4: 99-112.
31. Tanzi RE, Gusella JF, Watkins PC, et al. Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science 1987; 235: 880-84.
32. Goate A, Chartier-Harlin MC, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991; 349: 704-06.
33. Sherrington R, Rogaev EI, Liang Y, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995; 375: 754-60.
34. Rogaev EI, Sherrington R, Rogaeva EA, et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 1995; 376: 775-78.
35. Levy-Lahad E, Wasco W, Poorkaj P, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 1995; 269: 973-77.
36. Bettens K, Sleegers K, Van Broeckhoven C. Genetic insights in Alzheimer's disease. Lancet Neurol 2013; 12: 92-104.
37. Jonsson T, Atwal JK, Steinberg S, et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 2012; 488: 96-99.
38. Hardy J. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J Neurochem 2009; 110: 1129-34.
39. Pimplikar SW, Nixon RA, Robakis NK, Shen J, Tsai LH. Amyloid-independent mechanisms in Alzheimer's disease pathogenesis. J Neurosci 2010; 30: 14946-54.
40. Karlstrom H, Brooks WS, Kwok JB, et al. Variable phenotype of Alzheimer's disease with spastic paraparesis. J Neurochem 2008; 104: 573-83.
41. Roks G, Van Harskamp F, De Koning I, et al. Presentation of amyloidosis in carriers of the codon 692 mutation in the amyloid precursor protein gene (APP692). Brain 2000; 123: 2130-40.
42. Jayadev S, Leverenz JB, Steinbart E, et al. Alzheimer's disease phenotypes and genotypes associated with mutations in presenilin 2. Brain 2010; 133: 1143-54.
43. Guerreiro RJ, Baquero M, Blesa R, et al. Genetic screening of Alzheimer's disease genes in Iberian and African samples yields novel mutations in presenilins and APP. Neurobiol Aging 2010; 31: 725-31.
44. Pericak-Vance MA, Haines JL. Alzheimer's disease. In: King RA, Rotter JI, eds. The genetic basis of common diseases, 2nd edn. Oxford: Oxford University Press, 2002: 818-30.
45. Farrer LA, Brin MF, Elsas L, et al. American College of Medical Genetics/American Society of Human Genetics Working Group on ApoE and Alzheimer's Disease: statement on use of apolipoprotein E testing for Alzheimer's disease. JAMA 1995; 274: 1627-29.
46. Paulson HL, Igo I. Genetics of dementia. Semin Neurol 2011; 31: 449-60.
47. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's disease. Lancet 2011; 377: 1019-31.
48. Guerreiro R, Wojtas A, Bras J, et al. TREM2 variants in Alzheimer's disease. N Engl J Med 2013; 368: 117-27.
49. Jonsson T, Stefansson H, Steinberg S, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med 2013; 368: 107-16.
50. Chouery E, Delague V, Bergougnoux A, Koussa S, Serre JL, Megarbane A. Mutations in TREM2 lead to pure early-onset dementia without bone cysts. Hum Mutat 2008; 29: E194-204.
51. Green RC, Cupples LA, Go R, et al. Risk of dementia among white and African American relatives of patients with Alzheimer disease. JAMA 2002; 287: 329-36.
52. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998; 51: 1546-54.
53. Rascovsky K, Hodges JR, Kipps CM, et al. Diagnostic criteria for the behavioral variant of frontotemporal dementia (bvFTD): current limitations and future directions. Alzheimer Dis Assoc Disord 2007; 21: S14-18.
54. Seelaar H, Rohrer JD, Pijnenburg YA, Fox NC, van Swieten JC. Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. J Neurol Neurosurg Psychiatry 2011; 82: 476-86.
55. Whitwell JL, Josephs KA. Neuroimaging in frontotemporal lobar degeneration-predicting molecular pathology. Nat Rev Neurol 2011; 8: 131-42.
56. Hodges JR, Davies RR, Xuereb JH, et al. Clinicopathological correlates in frontotemporal dementia. Ann Neurol 2004; 56: 399-406.
57. Rohrer JD, Warren JD. Phenotypic signatures of genetic frontotemporal dementia. Curr Opin Neurol 2011; 24: 542-49.
58. Rascovsky K, Hodges JR, Kipps CM, et al. Diagnostic criteria for the behavioral variant of frontotemporal dementia (bvFTD): current limitations and future directions. Alzheimer Dis Assoc Disord 2007; 21: S14-18.
59. Henry ML, Gorno-Tempini ML. The logopenic variant of primary progressive aphasia. Curr Opin Neurol 2010; 23: 633-37.
60. Sajjadi SA, Patterson K, Arnold RJ, Watson PC, Nestor PJ. Primary progressive aphasia: a tale of two syndromes and the rest. Neurology 2012; 78: 1670-77.
61. Mackenzie IR, Neumann M, Bigio EH, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol 2010; 119: 1-4.
62. Hodges JR, Mitchell J, Dawson K, et al. Semantic dementia: demography, familial factors and survival in a consecutive series of 100 cases. Brain 2010; 133: 300-06.
63. Mackenzie IR, Rademakers R, Neumann M. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol 2010; 9: 995-1007.
64. Loy CT, McCusker E, Kril JJ, et al. Very early-onset frontotemporal dementia with no family history predicts underlying fused in sarcoma pathology. Brain 2010; 133: e158; author reply e9.
65. See TM, LaMarre AK, Lee SE, Miller BL. Genetic causes of frontotemporal degeneration. J Geriatr Psychiatry Neurol 2010; 23: 260-68.
66. Mahoney CJ, Beck J, Rohrer JD, et al. Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features. Brain 2012; 135: 736-50.
67. Rohrer JD, Guerreiro R, Vandrovcova J, et al. The heritability and genetics of frontotemporal lobar degeneration. Neurology 2009; 73: 1451-56.
68. Hutton M, Lendon CL, Rizzu P, et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998; 393: 702-05.
69. Brandt R, Hundelt M, Shahani N. Tau alteration and neuronal degeneration in tauopathies: mechanisms and models. Biochim Biophys Acta 2005; 1739: 331-54.
70. Baker M, Mackenzie IR, Pickering-Brown SM, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 2006; 442: 916-19.
71. Cruts M, Gijselinck I, van der See J, et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 2006; 442: 920-24.
72. Finch N, Baker M, Crook R, et al. Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. Brain 2009; 132: 583-91.
73. Ward ME, Miller BL. Potential mechanisms of progranulin-deficient FTLD. J Mol Neurosci 2011; 45: 574-82.
74. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011; 72: 245-56.
75. Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011; 72: 257-68.
76. Dobson-Stone C, Hallupp M, Bartley L, et al. C9ORF72 repeat expansion in clinical and neuropathologic frontotemporal dementia cohorts. Neurology 2012; 79: 995-1001.
77. van Blitterswijk M, van Es MA, Hennekam EA, et al. Evidence for an oligogenic basis of amyotrophic lateral sclerosis. Hum Mol Genet 2012; 21: 3776-84.
78. Le Ber I, Camuzat A, Hannequin D, et al. Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological, imaging and genetic study. Brain 2008; 131: 732-46.
79. Byrne S, Elamin M, Bede P, et al. Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study. Lancet Neurol 2012; 11: 232-40.
80. Majounie E, Renton AE, Mok K, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol 2012; 11: 323-30.
81. Watts GD, Wymer J, Kovach MJ, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet 2004; 36: 377-81.
82. Vance C, Rogelj B, Hortobagyi T, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 2009; 323: 1208-11.
83. Blair IP, Williams KL, Warraich ST, et al. FUS mutations in amyotrophic lateral sclerosis: clinical, pathological, neurophysiological and genetic analysis. J Neurol Neurosurg Psychiatry 2010; 81: 639-45.
84. Snowden JS, Hu Q, Rollinson S, et al. The most common type of FTLD-FUS (aFTLD-U) is associated with a distinct clinical form of frontotemporal dementia but is not related to mutations in the FUS gene. Acta Neuropathol 2011; 122: 99-110.
85. Skibinski G, Parkinson NJ, Brown JM, et al. Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nat Genet 2005; 37: 806-08.
86. Munch C, Rosenbohm A, Sperfeld AD, et al. Heterozygous R1101K mutation of the DCTN1 gene in a family with ALS and FTD. Ann Neurol 2005; 58: 777-80.
87. Halliday GM, Song YJ, Lepar G, et al. Pick bodies in a family with presenilin-1 Alzheimer's disease. Ann Neurol 2005; 57: 139-43.
88. Dermaut B, Kumar-Singh S, Engelborghs S, et al. A novel presenilin 1 mutation associated with Pick's disease but not beta-amyloid plaques. Ann Neurol 2004; 55: 617-26.
89. Borroni B, Archetti S, Del Bo R, et al. TARDBP mutations in frontotemporal lobar degeneration: frequency, clinical features, and disease course. Rejuvenation Res 2010; 13: 509-17.
90. Goldman JS, Rademakers R, Huey ED, et al. An algorithm for genetic testing of frontotemporal lobar degeneration. Neurology 2011; 76: 475-83.
91. Chen-Plotkin AS, Martinez-Lage M, Sleiman PM, et al. Genetic and clinical features of progranulin-associated frontotemporal lobar degeneration. Arch Neurol 2011; 68: 488-97.
92. Rademakers R, Baker M, Gass J, et al. Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477CaT (Arg493X) mutation: an international initiative. Lancet Neurol 2007; 6: 857-68.
93. Snowden JS, Rollinson S, Thompson JC, et al. Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations. Brain 2012; 135: 693-708.
94. Pearson JP, Williams NM, Majounie E, et al. Familial frontotemporal dementia with amyotrophic lateral sclerosis and a shared haplotype on chromosome 9p. J Neurol 2011; 258: 647-55.
95. Whitwell JL, Weigand SD, Boeve BF, et al. Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. Brain 2012; 135: 794-806.
96. Al-Sarraj S, King A, Troakes C, et al. p62 positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTLD and MND/ALS. Acta Neuropathol 2011; 122: 691-702.
97. Hutchinson AD, Mathias JL. Neuropsychological deficits in frontotemporal dementia and Alzheimer's disease: a meta-analytic review. J Neurol Neurosurg Psychiatry 2007; 78: 917-28.
98. Stevens M, van Duijn CM, Kamphorst W, et al. Familial aggregation in frontotemporal dementia. Neurology 1998; 50: 1541-45.
99. Collins SJ, Lawson VA, Masters CL. Transmissible spongiform encephalopathies. Lancet 2004; 363: 51-61.
100. Mead S. Prion disease genetics. Eur J Hum Genet 2006; 14: 273-81.
101. Boxer AL, Rabinovici GD, Kepe V, et al. Amyloid imaging in distinguishing atypical prion disease from Alzheimer disease. Neurology 2007; 69: 283-90.
102. Jayadev S, Nochlin D, Poorkaj P, et al. Familial prion disease with Alzheimer disease-like tau pathology and clinical phenotype. Ann Neurol 2011; 69: 712-20.
103. Godbolt AK, Cipolotti L, Watt H, Fox NC, Janssen JC, Rossor MN. The natural history of Alzheimer disease: a longitudinal presymptomatic and symptomatic study of a familial cohort. Arch Neurol 2004; 61: 1743-48.
104. Walker FO. Huntington's disease. Lancet 2007; 369: 218-28.
105. Paulsen JS, Langbehn DR, Stout JC, et al. Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry 2008; 79: 874-80.
106. Racette BA, Perlmutter JS. Levodopa responsive parkinsonism in an adult with Huntington's disease. J Neurol Neurosurg Psychiatry 1998; 65: 577-79.
107. Stevanin G, Fujigasaki H, Lebre AS, et al. Huntington's disease-like phenotype due to trinucleotide repeat expansions in the TBP and JPH3 genes. Brain 2003; 126: 1599-603.
108. Schneider SA, Walker RH, Bhatia KP. The Huntington's disease-like syndromes: what to consider in patients with a negative Huntington's disease gene test. Nat Clin Pract Neurol 2007; 3: 517-25.
109. Durr A. Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond. Lancet Neurol 2010; 9: 885-94.
110. Anheim M, Tranchant C, Koenig M. The autosomal recessive cerebellar ataxias. N Engl J Med 2012; 366: 636-46.
111. Le Pira F, Zappala G, Saponara R, et al. Cognitive findings in spinocerebellar ataxia type 2: genetic and clinical variables. J Neurol Sci 2002; 201: 53-57.
112. MaruffP, Tyler P, Burt T, Currie B, Burns C, Currie J. Cognitive deficits in Machado-Joseph disease. Ann Neurol 1996; 40: 421-27.
113. Koide R, Kobayashi S, Shimohata T, et al. A neurological disease caused by an expanded CAG trinucleotide repeat in the TATA-binding protein gene: a new polyglutamine disease? Hum Mol Genet 1999; 8: 2047-53.
114. Kanazawa I. Dentatorubral-pallidsoluysian atrophy or Naito-Oyanagi disease. Neurogenetics 1998; 2: 1-17.
115. Seniow J, Bak T, Gajda J, Poniatowska R, Czlonkowska A. Cognitive functioning in neurologically symptomatic and asymptomatic forms of Wilson's disease. Mov Disord 2002; 17: 1077-83.
116. Bennett J, Hahn SH. Clinical molecular diagnosis of Wilson disease. Semin Liver Dis 2011; 31: 233-38.
117. Ala A, Walker AP, Ashkan K, Dooley JS, Schilsky ML. Wilson's disease. Lancet 2007; 369: 397-408.
118. Sevin M, Lesca G, Baumann N, et al. The adult form of Niemann-Pick disease type C. Brain 2007; 130: 120-33.
119. Perez-Poyato MS, Pineda M. New agents and approaches to treatment in Niemann-Pick type C disease. Curr Pharm Biotechnol 2011; 12: 897-901.
120. Di Rocco M, Biancheri R, Rossi A, Filocamo M, Tortori-Donati P. Genetic disorders affecting white matter in the pediatric age. Am J Med Genet B Neuropsychiatr Genet 2004; 129B: 85-93.
121. Herve D, Chabriat H. CADASIL. J Geriatr Psychiatry Neurol 2010; 23: 269-76.
122. Adib-Samii P, Brice G, Martin RJ, Markus HS. Clinical spectrum of CADASIL and the effect of cardiovascular risk factors on phenotype: study in 200 consecutively recruited individuals. Stroke 2010; 41: 630-34.
123. Razvi SSM, Davidson R, Bone I, Muir KW. The prevalence of cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL) in the west of Scotland. J Neurol Neurosurg Psychiatry 2005; 76: 739-41.
124. Merwick A, O'Brien M, Delanty N. Complex single gene disorders and epilepsy. Epilepsia 2012; 53 (suppl 4): 81-91.
125. Noskova L, Stranecky V, Hartmannova H, et al. Mutations in DNAJC5, encoding cysteine-string protein alpha, cause autosomal-dominant adult-onset neuronal ceroid lipofuscinosis. Am J Hum Genet 2011; 89: 241-52.
126. MacMillan JC, Harper PS. Single-gene neurological disorders in South Wales: an epidemiological study. Ann Neurol 1991; 30: 411-14.
127. Bonifati V. Recent advances in the genetics of dementia with lewy bodies. Curr Neurol Neurosci Rep 2008; 8: 187-89.
128. Nervi A, Reitz C, Tang M-X, et al. Familial aggregation of dementia with Lewy bodies. Arch Neurol 2011; 68: 90-93.
129. Harding AJ, Das A, Kril JJ, Brooks WS, Duffy D, Halliday GM. Identification of families with cortical Lewy body disease. Am J Med Genet B Neuropsychiatr Genet 2004; 128B: 118-22.
130. Reid WG, Hely MA, Morris JG, Loy C, Halliday GM. Dementia in Parkinson's disease: a 20-year neuropsychological study (Sydney Multicentre Study). J Neurol Neurosurg Psychiatry 2011; 82: 1033-37.
131. Lippa CF, Duda JE, Grossman M, et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 2007; 68: 812-19.
132. Hardy J, Lewis P, Revesz T, Lees A, Paisan-Ruiz C. The genetics of Parkinson's syndromes: a critical review. Curr Opin Genet Dev 2009; 19: 254-65.
133. Goker-Alpan O, Giasson BI, Eblan MJ, et al. Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurology 2006; 67: 908-10.
134. Cohn-Hokke PE, Elting MW, Pijnenburg YA, van Swieten JC. Genetics of dementia: update and guidelines for the clinician. Am J Med Genet B Neuropsychiatr Genet 2012; 159B: 628-43.
135. Alzheimer's Society. Support with Familial Alzheimer's disease. http://forum.alzheimers.org.uk/showthread.php?42880-Supportwith-Familial- Alzheimers-disease (accessed Feb 21, 2013).
136. Alzheimer's Association. The Search for Alzheimer's Causes and Risk Factors. http://www.alz.org/research/science/alzheimers-disease-causes.asp (accessed Feb 21, 2013).
137. International Huntington Association and the World Federation of Neurology Research Group on Huntington's Chorea. Guidelines for the molecular genetics predictive test in Huntington's disease. J Med Genet 1994; 31: 555-59.
138. Posner K, Brown GK, Stanley B, et al. The Columbia-suicide severity rating scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 2011; 168: 1266-77.
139. Van Rij MC, De Rademaeker M, Moutou C, et al. Preimplantation genetic diagnosis (PGD) for Huntington's disease: the experience of three European centres. Eur J Hum Genet 2012; 20: 368-75.
140. Bamshad MJ, Ng SB, Bigham AW, et al. Exome sequencing as a tool for mendelian disease gene discovery. Nature Rev Genet 2011; 12: 745-55.
141. Guerreiro RJ, Lohmann E, Kinsella E, et al. Exome sequencing reveals an unexpected genetic cause of disease: Notch3 mutation in a Turkish family with Alzheimer's disease. Neurobiol Aging 2012; 33: 1008 e17-23.
142. Johnson JO, Mandrioli J, Benatar M, et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron 2010; 68: 857-64.
143. Montenegro G, Powell E, Huang J, et al. Exome sequencing allows for rapid gene identification in a Charcot-Marie-Tooth family. Ann Neurol 2011; 69: 464-70.
144. Lifton RP. Individual genomes on the horizon. N Engl J Med 2010; 362: 1235-36.